Related Experiment Video

Updated: May 24, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Molecular signaling and the role of targeted therapies in bladder cancer

P C Black1

  • 1Department of Urologic Sciences, University of British Columbia, Vancouver, BC, USA. peter.black@ubc.ca

Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology
|March 10, 2012
PubMed

Insights

Targeted therapies for bladder cancer are emerging, focusing on molecular targets driving cancer growth and spread. While still developing, new agents show promise in preclinical models for future clinical trials.

Area of Science:

  • Oncology
  • Molecular Biology
  • Urothelial Carcinomas

Background:

  • Understanding molecular mechanisms of urothelial transformation, growth, invasion, and metastasis in bladder cancer is advancing.
  • A growing number of targeted agents are available, with clinical experience in other cancers potentially lowering barriers for bladder cancer use.

Purpose of the Study:

  • To review well-characterized and promising molecular targets for bladder cancer therapy.
  • To summarize the clinical experience with targeted agents against these pathways.
  • To describe novel agents with preclinical potential.

Main Methods:

  • Literature review of molecular targets in bladder cancer.
  • Analysis of clinical trial data for targeted agents.
  • Evaluation of preclinical data for novel therapeutic agents.

Main Results:

  • Targeted therapy for bladder cancer is in its early stages with no major breakthroughs yet.
  • Several molecular targets and pathways have been identified as suitable for novel targeted therapies.
  • Novel agents show significant potential in preclinical models.

Conclusions:

  • Continued research into molecular mechanisms is crucial for developing effective targeted therapies for bladder cancer.
  • Despite early challenges, targeted therapy holds future promise for bladder cancer treatment.
  • Further clinical investigation of novel agents is warranted.

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...